Drug intelligence / Profile preview

pefcalcitol

Development stage: Phase 3
Lead developer: Chugai Pharmaceutical
Modality: Small Molecules
Administration: Topical

Overview

Pefcalcitol is a synthetic vitamin D3 analog developed for topical use, primarily investigated for the treatment of psoriasis. It acts as an agonist of the vitamin D receptor (VDR), modulating gene expression to inhibit keratinocyte proliferation and promote differentiation in the skin. This mechanism helps reduce psoriatic plaque formation and inflammation. Pefcalcitol was designed to have high efficacy with reduced risk of hypercalcemia compared to other vitamin D analogs.

Other names: pefcalcitol

Targets

VDR (Vitamin D receptor)

Beyond the preview

Go deeper on pefcalcitol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pefcalcitol.

Explore the full profile